Beijing Tong Ren Tang Chinese Medicine Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Wang Chi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO
Wang Chi (49 yo)
less than a year
Tenure
Mr. Wang Chi is Executive Director and Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited from May 10, 2024. Mr. Chi has experience in Medical and Pharmaceutical industry. Mr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | less than a year | no data | no data | |
| Executive Director & Executive Deputy GM | less than a year | HK$975.00k | 0.0073% € 63.6k | |
| CEO & Executive Director | less than a year | no data | no data | |
| CFO & Company Secretary | 4.6yrs | no data | no data | |
| Deputy GM & General Counsel | no data | no data | no data |
0.8yrs
Average Tenure
50yo
Average Age
Experienced Management: TQR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | less than a year | no data | no data | |
| Executive Director & Executive Deputy GM | 4.8yrs | HK$975.00k | 0.0073% € 63.6k | |
| CEO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.3yrs | HK$288.00k | no data | |
| Independent Non-Executive Director | 11.7yrs | HK$288.00k | no data | |
| Non-Executive Director | 2.3yrs | no data | no data | |
| Independent Non-Executive Director | 1.8yrs | HK$240.00k | no data |
2.3yrs
Average Tenure
53yo
Average Age
Experienced Board: TQR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 20:21 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Tong Ren Tang Chinese Medicine Company Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| null null | CMB International Securities Limited |
| Christina Chen | HSBC |